Drug Delivery

Nasal Drug Spray Testing

Aerosol, spray, dose, breathing simulation, and stability testing for nasal drug spray devices and formulations.

Testing combines NGI with nasal fixtures, laser diffraction, APS, dose collection, breathing profiles, and HPLC or ELISA quantitation selected for the active.

ISO 17025USP <601>USP <1601>FDA MDI / DPI / nasalReviewed 2026-05-17
Request a quoteSubmit a sample

Testing nasal drug spray devices

Nasal drug spray testing generates the in vitro performance data sponsors need to select pumps, compare formulations, document change control, and support submission packages. USP <601>, USP <1601>, FDA nasal spray guidance, and ICH Q1A provide the core measurement framework for droplet size, spray geometry, dose output, breathing-interface behavior, and stability trending when:

  1. PSD by laser diffraction, APS, or NGI compares nasal spray droplet and aerodynamic profiles under USP <601> and FDA nasal guidance.
  2. Spray pattern and plume geometry document actuator, nozzle, pump, or formulation changes for FDA comparability and change-control packages.
  3. Delivered dose and emitted dose series quantify actuation variability, priming, and container-life effects under USP <601> and USP <1601>.
  4. Breathing simulation estimates inhaled or beyond-nose fraction using nasal fixtures, interface geometry, and FDA use-condition framing.
  5. Stability pulls track PSD, plume, dose, assay, and device behavior after ICH Q1A temperature and RH conditioning.

Nasal spray testing is appropriate when device output, formulation state, actuation settings, or storage history may affect delivered performance. Before samples arrive, a defined protocol connects fixture geometry, actuation sequence, particle measurement, analytical recovery, and acceptance logic.

Core testing menu for nasal drug spray devices

Nasal spray programs draw on five measurement disciplines. Studies may use a single endpoint or combine several based on the formulation stage, comparator strategy, use condition, and regulatory framework.

Test method options

MethodStrengthsTradeoffAligned with
Submission-grade PSD and APSD package
  • Laser diffraction plus NGI collection quantifies droplet size, MMAD, GSD, and small-particle fraction under USP <601>.
  • Recovery controls and nasal fixtures connect stage mass to FDA nasal spray comparability and submission support.
Higher setup and assay burden than screening; best after pump, nozzle, formulation, and collection conditions are selected.
USP <601>FDA MDI / DPI / nasal
Spray pattern and plume geometry study
  • Laser sheet imaging resolves spray footprint, plume angle, width, and distribution for FDA change-control studies.
  • Controlled distance, timing, and actuation settings isolate pump, actuator, nozzle, or formulation effects.
Geometric imaging does not replace APSD or dose data when regulators require active-mass endpoints.
FDA MDI / DPI / nasalISO 27427
Dose uniformity and emitted dose series
  • Multi-actuation sequences measure delivered dose, emitted dose, priming, repriming, and container-life effects under USP <601>.
  • HPLC, ELISA, qPCR, or ddPCR recovery links collection mass to active-specific dose statistics.
Collection adapters and actuation settings must match device geometry before meaningful lot comparisons can start.
USP <601>USP <1601>FDA MDI / DPI / nasal
Breathing-interface and use-condition simulation
  • Programmable profiles pair actuation timing, nasal fixtures, and recovery locations to estimate inhaled fraction under USP <601>.
  • Profile sweeps support FDA use-condition comparisons without changing the active assay or device state.
Results depend on fixture assumptions, leakage, and profile selection; those assumptions must be declared up front.
USP <601>ISO 27427FDA MDI / DPI / nasal
Stability-linked performance trending
  • Conditioned pulls track PSD, plume, emitted dose, assay, and pump function across ICH Q1A storage timepoints.
  • Distribution or handling conditioning can add ASTM D4169 stress before post-aging nasal spray performance checks.
Study duration follows storage and pull timing; analytical scheduling should be planned before conditioning begins.
ICH Q1AASTM D4169

Setup configurations

ARE Labs configures each nasal spray study around the device geometry, formulation state, collection endpoint, and regulatory use case. A single product may require different fixtures for droplet sizing, APSD, plume imaging, dose recovery, breathing simulation, or stability pulls. Before testing begins, the study plan defines actuation settings, environmental controls, assay recovery, and replicate structure.

Interfaces & fixtures

Nasal adapters, throat models, bottle holders, and recovery fixtures matched to the pump, actuator, nozzle, and container geometry.

Actuation profiles

Manual, semi-automated, or automated actuation with force, stroke, speed, priming, repriming, shot interval, and orientation recorded per run.

Flows & breathing profiles

Collection flow, breathing waveform, sampling location, and fixture leakage controls set to the endpoint and use-condition question.

Sample numbers

Device count, lot count, spray count, life stage, and replicate count sized to screening, comparability, stability, or submission support.

Conditioning & controls

Temperature, RH, storage orientation, blanks, reference devices, recovery locations, assay controls, and acceptance criteria defined before interpretation.

Quality frame for nasal spray testing

Nasal spray studies are conducted within a documented quality system anchored to the compendial and regulatory references most often used for intranasal drug products and development decisions.

  • ISO 17025AccreditedLaboratory competence, calibration traceability, method control, and uncertainty contributors.
  • USP <601>AccreditedAerosols, nasal sprays, APSD, delivered dose, and spray-performance tests.
  • USP <1601>AlignedInhalation and intranasal product characterization language used where applicable.
  • FDA MDI / DPI / nasalAlignedCMC expectations for nasal spray product quality attributes and changes.

Key data outputs & reporting

Each nasal spray program receives an endpoint-specific dataset that connects the device setup to measured performance. Deliverables may include PSD tables, APSD recovery, emitted-dose statistics, plume images, breathing-profile recovery, assay controls, and QA/QC records. Reports are structured for development review, method justification, comparability packages, or stability trend interpretation. When a program includes predicate comparisons or storage pulls, extended deliverables provide the necessary appendices.

Primary outputs

  • Droplet size distribution, APSD stage mass, MMAD, GSD, small-particle fraction, and impactor recovery by device or condition.
  • Spray pattern area, circularity, plume angle, plume width, distance setting, actuation timing, and image files.
  • Delivered dose, emitted dose, priming, repriming, beginning/middle/end-of-life statistics, mean, SD, and %RSD.
  • Breathing-profile recovery by fixture location with profile assumptions, flow settings, leakage notes, and interpretation limits.

Deliverables

#FormatContents
01PDF reportProtocol summary, setup, controls, deviations, results, and interpretation limits.
02CSV / XLSX datasetsParticle sizing, stage mass, dose statistics, recovery, and assay tables.
03Images / videoSpray pattern files, plume frames, overlays, and high-speed exports when used.
Extended deliverables · multi-arm comparability · stability · predicate studies
  • Comparability appendix — Side-by-side PSD, APSD, plume, and dose summaries for reference, predicate, or design-change review.
  • Stability trend pack — Timepoint tables and figures showing dose, size, plume, assay, and device-function drift.
  • Method-development notes — Fixture rationale, control runs, recovery constraints, and uncertainty contributors for inspection readiness.

QA / QC & data integrity

Each nasal spray study includes a QA/QC plan matched to the selected endpoints, assay, and regulatory framework. Controls are run alongside sample collection so particle, plume, dose, and breathing-simulation data remain traceable from sample receipt through the final report. Method deviations, invalid runs, and contributors to uncertainty are documented instead of being obscured in summary tables.

Blanks, background checks, comparator devices, or reference runs defined by endpoint and collection train.

Flow meters, balances, impactor stages, imaging scales, timers, and actuation fixtures checked or calibrated before use.

Assay controls for HPLC, ELISA, qPCR, or ddPCR, including calibration standards and recovery checks when required.

Chain of custody for devices, collected stages, filters, extracts, raw files, image files, and analyst observations.

Predefined acceptance criteria, replicate rules, deviation handling, and outlier logic included in the protocol.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)
QualityDocumented study records
900+Studies Performed
17+Years in operation
300+Clients supported

Common questions

These answers address common questions from nasal drug spray development and regulatory teams, including which endpoints to combine, how devices and actuations are counted, how breathing simulation affects the study, and what documentation is delivered. Most nasal spray programs require at least one custom decision about the fixture, actuation, or assay, which is best resolved during study planning.

Q.Which nasal spray test should I start with?
A.Begin with the decision the data need to support. PSD describes size distribution, plume imaging shows spray formation, dose testing measures output consistency, breathing simulation evaluates recovery under use conditions, and stability testing measures the effects of storage.
Q.Do I need both plume geometry and PSD?
A.Often, yes. Spray pattern and plume geometry characterize spray formation, while PSD and APSD describe particle or droplet size behavior. Submission and comparability packages commonly require both endpoint families.
Q.How many devices or actuations are needed?
A.Device, lot, shot, life-stage, and replicate counts depend on expected variability, assay sensitivity, and whether the study is intended for screening or submission support. ARE Labs defines these counts during protocol development.
Q.Can ARE Labs test solution and suspension sprays?
A.Yes. The protocol can address solution or suspension behavior, including shaking, settling, recovery, active assay, droplet size, emitted dose, and stability-linked performance checks.
Q.Does this certify or approve a nasal spray product?
A.No. ARE Labs focuses on aerosol, emitted dose, breathing simulation, assay, and stability testing. Sponsors may still require separate clinical, bioequivalence, labeling, submission, and quality-system work.

Standards & guidance

ARE Labs aligns nasal spray test programs with the compendial, consensus, and regulatory references used to characterize intranasal drug products. Accredited work is identified as accredited; other references are described as aligned or conformant where applicable. The rows below list the standards and guidance clusters most often cited for nasal spray sizing, plume, dose, breathing-interface, and stability support.

Inhalation & Drug Delivery - Accredited

USP <601>

Aerosols, nasal sprays, APSD, delivered dose, and performance quality testsView standard ->Inhalation & Drug Delivery - Aligned

USP <1601>

Inhalation and intranasal product characterization language used for dose and performance studiesView standard ->QA & Regulatory - Aligned

FDA MDI / DPI / nasal

Quality considerations for nasal spray products, comparability, device changes, and CMC supportView standard ->Inhalation & Drug Delivery - Aligned

ISO 27427

Nebulizing system performance concepts used where breathing-interface evaluation appliesView standard ->QA & Regulatory - Aligned

ICH Q1A

Stability storage conditions, pull timing, and trend interpretation for drug productsView standard ->Packaging & Stability - Aligned

ASTM D4169

Distribution-cycle conditioning before post-stress nasal spray performance evaluationView standard ->

Related testing services

Test

Particle Size Distribution (PSD) Testing

Pairs with nasal spray dose testing to quantify droplet size, APSD, MMAD, GSD, and small-particle fraction.Read more ->Test

Spray Pattern & Plume Geometry

Documents pump, actuator, nozzle, and formulation effects on plume shape, spray footprint, and spray distribution.Read more ->Test

Dose Uniformity & Emitted Dose

Core nasal spray output test for actuation consistency, priming, repriming, and container-life dose behavior.Read more ->Test

Breathing Simulation Testing

Adds use-condition profiles, nasal fixtures, interface geometry, and recovery locations for inhaled or beyond-nose fraction questions.Read more ->Test

Stability & Accelerated Aging

Pairs storage pulls and conditioning with nasal spray PSD, plume, dose, assay, and pump-function trending.Read more ->